title: Inhibition of tissue angiotensin converting enzyme. Quantitation by autoradiography.
abstract: Inhibition of angiotensin converting enzyme (ACE) in serum and tissues of rats was studied after administration of lisinopril, an ACE inhibitor. Tissue ACE was assessed by quantitative in vitro autoradiography using the ACE inhibitor [125I]351A, as a ligand, and serum ACE was measured by a fluorimetric method. Following oral administration of lisinopril (10 mg/kg), serum ACE activity was acutely reduced but recovered gradually over 24 hours. Four hours after lisinopril administration, ACE activity was markedly inhibited in kidney (11% of control level), adrenal (8%), duodenum (8%), and lung (33%; p less than 0.05). In contrast, ACE in testis was little altered by lisinopril (96%). In brain, ACE activity was markedly reduced 4 hours after lisinopril administration in the circumventricular organs, including the subfornical organ (16-22%) and organum vasculosum of the lamina terminalis (7%; p less than 0.05). In other areas of the brain, including the choroid plexus and caudate putamen, ACE activity was unchanged. Twenty-four hours after administration, ACE activity in peripheral tissues and the circumventricular organs of the brain had only partially recovered toward control levels, as it was still below 50% of control activity levels. These results establish that lisinopril has differential effects on inhibiting ACE in different tissues and suggest that the prolonged tissue ACE inhibition after a single oral dose of lisinopril may reflect targets involved in the hypotensive action of ACE inhibitors.
authors.affiliation: Department of Medicine, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia.
authors.forename: K
authors.initials: K
authors.lastname: Sakaguchi
authors.forename: S Y
authors.initials: SY
authors.lastname: Chai
authors.forename: B
authors.initials: B
authors.lastname: Jackson
authors.forename: C I
authors.initials: CI
authors.lastname: Johnston
authors.forename: F A
authors.initials: FA
authors.lastname: Mendelsohn
mesh_terms: D000311:Adrenal Glands / Q000201:enzymology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D001345:Autoradiography; D001921:Brain / Q000201:enzymology; D004151:Dipeptides; D004386:Duodenum / Q000201:enzymology; D004656:Enalapril / Q000031:analogs & derivatives* / Q000494:pharmacology; D007457:Iodine Radioisotopes; D007668:Kidney / Q000201:enzymology; D017706:Lisinopril; D008168:Lung / Q000201:enzymology; D008297:Male; D007703:Peptidyl-Dipeptidase A / Q000032:analysis*; D051381:Rats; D011919:Rats, Inbred Strains; D012084:Renin-Angiotensin System / Q000187:drug effects; D013737:Testis / Q000201:enzymology; D013997:Time Factors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D004151:Dipeptides; D007457:Iodine Radioisotopes; C042037:L-proline, N2-((1S)-1-carboxy-3-phenylpropyl)-N6-((4-hydroxyphenyl)iminomethyl)-L-lysyl-; D004656:Enalapril; D017706:Lisinopril; D007703:Peptidyl-Dipeptidase A